The global antibody therapeutics market is forecasted to hit USD 479 billion by 2028, expanding at a CAGR of 14.1%. North America spearheads the market with major players like AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb. Europe's market is poised for substantial growth propelled by companies such as F. Hoffmann-La Roche Ltd., AstraZeneca, and Sanofi. Human source antibodies are predominant, with humanized sources exhibiting notable growth, and intravenous administration emerges as the prevalent route for antibody therapeutics.

Antibody Therapeutics Market Surge